Abstract | PURPOSE: METHODS: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. RESULTS: CONCLUSIONS: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.
|
Authors | Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 72
Issue 4
Pg. 853-60
(Oct 2013)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 23978988
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Everolimus
- Sirolimus
|
Topics |
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Asian People
- Carcinoma, Renal Cell
(drug therapy, pathology)
- Disease-Free Survival
- Drug Monitoring
(methods)
- Everolimus
- Female
- Humans
- Kidney Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Metastasis
- Republic of Korea
- Retrospective Studies
- Sirolimus
(adverse effects, analogs & derivatives, therapeutic use)
- Survival Rate
- Treatment Outcome
|